key: cord-0685945-nu5g9r1e
authors: Ali, Sajjad; Almas, Talal; Zaidi, Ujala; Ahmed, Farea; Shaikh, Sufyan; Shaikh, Fathema; Tafveez, Rida; Arsalan, Maaz; Antony, Ishan; Antony, Meetty; Sehar, Burhanuddin; Aborode, Abdullahi T.; Ali, Murtaza; Nagarajan, Vikneswaran Raj; Samy, Arjun; Alrawashdeh, Maen Monketh; Alkhattab, Maha; Ramjohn, Joshua; Ramjohn, Jeremy; Huang, Helen; Nawaz, Qassim Shah; Khan, Kashif Ahmad; Khullar, Shane
title: A novel case of lupus nephritis and mixed connective tissue disorder in a COVID-19 patient
date: 2022-04-23
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2022.103653
sha: 08fd450a54938af95fbdb4c6f1152d128c838ac6
doc_id: 685945
cord_uid: nu5g9r1e

INTRODUCTION: Mixed connective tissue disease (MCTD) is a rare autoimmune condition characterized by Scleroderma, Polymyositis, and Systemic Lupus Erythematous (SLE). Though a possible relationship between COVID-19 and autoimmune diseases has been recently reported, its pathophysiological mechanism behind flares in Lupus Nephritis (LN), a complication of SLE, remains unknown. CASE PRESENTATION: A 22-year-old COVID-19 positive female presented with anemia, bilateral pitting edema, periorbital swelling, and posterior cervical lymphadenitis. Further inspection revealed lower abdominal striae, hepatosplenomegaly, and hyperpigmented skin nodules. Complete blood counts showed elevated inflammatory markers and excessively high protein creatinine ratio. Antinuclear antibody titers were elevated (anti-smith and U1 small nuclear ribonucleoprotein) and Rheumatoid Factor was positive. She was diagnosed with MCTD associated with a flare of LN. To control her lupus flare, a lower dose of steroids was initially administered, in addition to oral hydroxychloroquine and intravenous cyclophosphamide. Her condition steadily improved and was discharged on oral steroid maintenance medication. DISCUSSION: We present a rare phenomenon of newly diagnosed LN, a complication of SLE, with MCTD in a PCR-confirmed COVID-19 patient. The diagnostic conundrum and treatment hurdles should be carefully addressed when patients present with lupus and COVID-19 pneumonia, with further exploration of the immuno-pathophysiology of COVID-19 infection in multi-systemic organ dysfunction in autoimmune disorders. CONCLUSION: In COVID-19 patients with LN and acute renal injury, it is critical to promptly and cautiously treat symptomatic flares associated with autoimmune disorders such as SLE and MCTD that may have gone unnoticed to prevent morbidity from an additional respiratory infection.

Mixed connective tissue disease (MCTD) is a rare autoimmune condition characterized by Scleroderma, Polymyositis, and Systemic Lupus Erythematous (SLE). Though a possible relationship between COVID-19 and autoimmune diseases has been recently reported, its pathophysiological mechanism behind flares in Lupus Nephritis (LN), a complication of SLE, remains unknown.

A 22-year-old COVID-19 positive female presented with anemia, bilateral pitting edema, periorbital swelling, and posterior cervical lymphadenitis. Further inspection revealed lower abdominal striae, hepatosplenomegaly, and hyperpigmented skin nodules. Complete blood counts showed elevated inflammatory markers and excessively high protein creatinine ratio. Antinuclear antibody titers were elevated (anti-smith and U1 small nuclear ribonucleoprotein) and Rheumatoid Factor was positive. She was diagnosed with MCTD associated with a flare of LN. To control her lupus flare, a lower dose of steroids was initially administered, in addition to oral hydroxychloroquine and intravenous cyclophosphamide. Her condition steadily improved and was discharged on oral steroid maintenance medication.

Mixed Connective Tissue Disease (MCTD) was initially identified in 1972 as a condition characterized by overlapping characteristics of systemic sclerosis, systemic lupus erythematosus (SLE), and the previous eight months. The fever was mild, intermittent, and alleviated by antipyretics. This was accompanied by frequent bowel movements (4-5 times per day) and progressive shortness of breath at rest and during exertion. However, there were no reports of orthopnea or paroxysmal nocturnal dyspnea. She also complained of polyuria and hematuria for the last two days. Her past medical history was insignificant, and other aspects of her health, including menstrual health, were unremarkable.

There is no history of chronic disease in her family.

Upon presentation to the emergency department, she was a-febrile, tachypneic but hemodynamically stable, and well oriented to time and place. On inspection, there was a noticeable pallor, indicating a positive anemic state. Dehydration, bilateral pitting edema up to the shin, and periorbital swelling were also seen. Posterior cervical lymph nodes (less than 0.4cm) and a lymph node (1 cm) in the right axilla were palpable. Painful, itchy, indurated, and hyperpigmented lesions [ Figure 1 ] were observed in various places of her body, as well as a history of hair loss, mouth ulcers, and mouth dryness.

Abdominal examinations revealed striae over the lower abdomen, a palpable spleen, and a liver with a 17-cm span. Furthermore, several cystic lesions were noticeable on breast examination, with the largest one measuring 1.4 x 0.9 cm in the right breast and 1.4 x 0.6 cm in the left breast. The lesions had a firmness and smooth edges.

Extensive investigations were carried out to rule out any potential diagnoses [ Table 1 ]. A Complete Blood Count (CBC) profile revealed that the patient had low hemoglobin levels. An in-depth analysis of anemia resulted in the reporting of an increased reticulocyte count. Other cell lines were also deranged, with a high leukocyte count and thrombocytopenia. Based on the findings, further screening of inflammatory markers, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), revealed unusually increased serum levels for both. Furthermore, the urine report was positive for protein, red blood cells, pus cells, granular casts, and urate but harmful for any infectious organism. The protein creatinine ratio was excessively high, indicating severe proteinuria. A comprehensive stool culture was also performed, which revealed the J o u r n a l P r e -p r o o f presence of mucus, red blood cells, pus cells, and yeast cells. Further investigation included viral markers, which were shown to be negative.

On suspicion of autoimmune disorders [ Table 2 ], antinuclear antibodies (ANA) titers were carried which were found to be elevated. Along with this, Extractable Nuclear Antigen (ENA) profile revealed an increase in antibody titers to the anti-smith (Sm) and U1 small nuclear ribonucleoprotein (U1-RNP).

Moreover, she was tested positive for Rheumatoid factor, while C3 and C4 complement levels were within range.

Ultrasonography was performed to thoroughly assess breast tissue, which revealed several cystic regions in the right breast, primarily in the upper quadrant. One measured 16.2 x 9.4 mm and extended into the retro-areolar area, displaying diffuse internal echoes. Multiple large lymph nodes measuring 16.0 x 9.4 mm were seen in the right axilla, along with hilar thinning. Multiple cystic regions were found dispersed throughout the parenchyma of the left breast, one of them being next to the areolar edge and measuring 15.8 x 6.8 mm. The discovered cysts were most likely complicated cysts.

The left axilla showed a few swollen lymph nodes measuring 22.0 x 10.0 mm, as well as thinning of the hilum.

Echocardiography was performed to rule out cardiac involvement, which was expected. Along with an endoscopy, a color Doppler of the lower limbs was performed. Endoscopy revealed minor pangastritis, and a biopsy was performed (results are awaited). A Doppler examination of the lower limbs revealed no indications of stenosis, occlusion, or thrombosis. However, it did indicate bilateral soft tissue edema and a benign-looking inguinal lymph node on the right side.

The on-call nephrologist ordered a renal biopsy for further confirmation, and the results are still pending. Based on the clinical findings and laboratory investigations, the patient was diagnosed with MCTD associated with a flare of LN.

Despite the initial concerns regarding the commencement of steroids in an active COVID-19 infection, the management team decided to control her lupus flare with a lower steroid dose (intravenous J o u r n a l P r e -p r o o f methylprednisolone 50mg once daily) throughout hospitalization, in addition to oral hydroxychloroquine 200mg once daily. The patient was also given 1g intravenous cyclophosphamide once a month. Her condition steadily improved, and she was stable on the 7 th day of her hospitalization. She was discharged on oral steroid maintenance medication with a follow-up appointment. At the follow-up appointment, the patient continues to do well with no evidence of recent flare-up and a complete resolution of her acute symptoms.

The present paper has been reported in accordance with the SCARE guidelines [14] .

We conducted a thorough review of the literature and collated all clinical cases of LN and/or MCTD linked with COVID-19 infection, taking into account their place of origin, age, sex, body systems involving the disease, its associated medical regimen, and the severity of COVID-19 condition. We (Table 2) . For lupus management, more than half (56.7%) of the patients were on hydroxychloroquine therapy.

Moreover, about half of the patients were given corticosteroids, while only nine were on mycophenolate mofetil.

We have analyzed and classified COVID-19 based on its severity, including asymptomatic, mild, moderate, severe, or critical. The majority of the patients (83.7 percent) were infected with mild to moderate COVID-19. In contrast, seven (18.9 percent) of the patients had severe to serious COVID-19. Similarly, another study showed the same results, stating that patients with Lupus and the general population share the same COVID-19 hospitalization risk factors [52] . However, Giuseppe A. Ramirez et al. [48] concluded that COVID-19 could have a moderately increased morbidity in patients suffering from SLE, even though the study had certain limitations and selection bias, rendering the possibility controversial. In addition, another complication arising from overlap in symptoms of rheumatic flare and COVID-19 was observed in a retrospective study conducted in Tongji hospital, which stated that the overlapped symptoms were a cause of increased morbidity due to delayed diagnosis in patients presenting with respiratory infection due to COVID-19 [53]. Our patient, who presented with COVID-19 results but was later identified with chronic MCTD associated with LN, was a case that was somewhat but not entirely similar. • Because of the overlapping clinical manifestations and laboratory findings between lupus and COVID-19 pneumonia, the diagnostic problems and treatment hurdles should be carefully addressed.

• In COVID-19 patients with LN flare and acute renal injury, it is critical to resolve any reversible causes of the kidney injury and manage the COVID-19 before treating the LN.

J o u r n a l P r e -p r o o f

Mixed connective tissue disease

Lupus: an overview of the disease and management options

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Clinical characteristics of Covid-19 in China

Atypical case of COVID-19 associated Kawasaki disease in an eightyear-old Pakistani boy

A review of cardiac complications in coronavirus disease 2019

Impact of chronic kidney disease on severity and mortality in COVID-19 patients: a systematic review and meta-analysis

The association of acute kidney injury with disease severity and mortality in COVID-19: a systematic review and meta-analysis

Association of Guillain-Barre syndrome with COVID-19: a case report and literature review

Respiratory viral infections and the risk of rheumatoid arthritis

COVID-19 and systemic lupus erythematosus: a case series

2021) A Flare of Systemic Lupus Erythematosus Disease After COVID-19 Infection: A Case of Lupus Cerebritis

The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines

Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination

Pericarditis as a Secondary Complication of COVID-19 in a Renal Transplant Patient

Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report

Abnormal immunothrombosis and lupus anticoagulant in a catastrophic COVID-19 recalling Asherson's syndrome

Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology

Acute Ischemic Stroke in a Lupus Anticoagulant-Positive Woman With COVID-19

A 31-Year-Old Man with COVID-19-Associated Empyema and Lupus Anticoagulant

COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration

Case report: A kidney transplant patient with mild COVID-19

No evidence of vertical transmission of SARS-CoV-2 after induction of labour in an immune-J o u r n a l P r e -p r o o f suppressed SARS-CoV-2-positive patient

COVID-19 and Acute Lupus Pneumonitis: Diagnostic and Treatment Dilemma

The COVID-19 outbreak and rheumatologic skin diseases

COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients

et alClinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort studyAnnals of the Rheumatic Diseases

The Plight of Patients with Lupus Nephritis during the Outbreak of COVID-19 in Wuhan

et alAre patients with systemic lupus erythematosus at increased risk for COVID-19?

Studies Show Similar COVID-19 Risk Factors for Patients with Lupus or Inflammatory Arthritis as General Population

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions.Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editorin-Chief of this journal on request.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. J o u r n a l P r e -p r o o f

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry: NA 2. Unique Identifying number or registration ID: NA

Hyperlink to your specific registration (must be publicly accessible and will be checked): NA

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish J o u r n a l P r e -p r o o f